Synaptotoxicity in Alzheimer's Disease: The Wnt Signaling Pathway as a Molecular Target
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Recent evidence supports a role of the Wnt pathway in neurodegenerative disorders such as Alzheimer's disease (AD). A relationship between amyloid‐β‐peptide (Aβ)‐induced neurotoxicity and a decrease in the cytoplasmatic levels of β‐catenin has been proposed. Also, the inhibition of glycogen synthase kinase (GSK‐3β), a central modulator of the pathway, protects rat hippocampal neurons from Aβ‐induced damage. Interestingly, during the progression of AD, it has been described that active GSK‐3β is found in neuronal cell bodies and neurites, co‐localizing with pre‐neurofibrillary tangles observed in disease brains. Since Aβ oligomers are associated with the post‐synaptic region and we have found that the non‐canonical Wnt signaling modulates PSD‐95 and glutamate receptors, we propose that the synaptic target for Aβ oligomers in AD is the postsynaptic region and at the molecular level is the non‐canonical Wnt signaling pathway. Altogether, our evidence suggests that a sustained loss of Wnt signaling function may be involved in the Aβ‐dependent neurodegeneration observed in AD brains and that the activation of this signaling pathway could be of therapeutic interest in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 1×
“Peroxisome proliferator activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcriptional factors acting as a hetero-dimer with the 9-cis retinoic acid receptor ( 23 ).”
BackgroundRegulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Veeman, M. T., Axelrod, J. D., & Moon, R. T. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00266-1 · Cited by 1,359
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss
Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., & Malinow, R. (2006) · Neuron · doi:10.1016/j.neuron.2006.10.035 · Cited by 1,042
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses
Almeida, C. G., Tampellini, D., Takahashi, R. H., Greengard, P., Lin, M. T., Snyder, E. M., & Gouras, G. K. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.02.008 · Cited by 397
Cited by
Depression and Alzheimer's disease: Neurobiological links and common pharmacological targets
Caraci, F., Copani, A., Nicoletti, F., & Drago, F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.022 · Cited by 314
Toledo, E. M., & Inestrosa, N. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.72 · Cited by 293
Self-citationMagdesian, M. H., Carvalho, M. M. V. F., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L., Garcia-Abreu, J., & Ferreira, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707108200 · Cited by 221
Liu, C.-C., Tsai, C.-W., Deak, F., Rogers, J., Penuliar, M., Sung, Y. M., Maher, J. N., Fu, Y., Li, X., Xu, H., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.048 · Cited by 222
“These findings suggest that misregulation of this pathway likely contributes to synaptic dysfunction in neurodegenerative diseases, including Alzheimer's disease (AD) (Inestrosa et al., 2007).”
Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8401-2 · Cited by 165
“In fact, recent studies concentrated on establishing the molecular complexity of Wnt/β-catenin signaling in neurons propose that inhibition of GSK-3β decreases Aβ neurotoxicity by reducing tau phosphorylation, increases β-catenin stabilization, and improves memory performance, suggesting that restoring β-catenin signa…”
Background
Metadata
- Authors
- Inestrosa, N. C., Varela‐Nallar, L., Grabowski, C. P., & Colombres, M.
- Venue
- IUBMB Life
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 59
- Issue
- 4-5
- Pages
- 316-321
- ISSN
- 1521-6543 (ISSN-L)
- 1521-6551
- OpenAlex
- W2129720310
- Cited by
- 67
- References
- 8
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synaptotoxicity in Alzheimer's Disease: The Wnt Signaling Pathway as a Molecular Target. https://app.cochat.ai/papers/10.1080/15216540701242490
- The paper
- Inestrosa, N. C., Varela‐Nallar, L., Grabowski, C. P., & Colombres, M. (2007). Synaptotoxicity in Alzheimer's Disease: The Wnt Signaling Pathway as a Molecular Target. IUBMB Life. https://doi.org/10.1080/15216540701242490
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.